DoD Rare Cancers, Idea Development Award
ID: 353641Type: Posted
Overview

Buyer

Dept. of the Army -- USAMRAA (DOD-AMRAA)

Eligible Applicants

Unrestricted

Funding Category

Science and Technology and other Research and Development

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/353641
Timeline
  1. 1
    Forecast Posted Not available
  2. 2
    Forecast Due Not available
  3. 3
    Posted Apr 19, 2024, 12:00 AM UTC
  4. 4
    Due Sep 23, 2024, 12:00 AM UTC
Description

The Department of the Army, through the U.S. Army Medical Research and Materiel Command (USAMRAA), is offering the FY24 Rare Cancers Research Program (RCRP) Idea Development Award to support innovative research aimed at addressing rare cancers, which are defined as those affecting six or fewer individuals per 100,000 annually in the U.S. This grant opportunity encourages applications that demonstrate a strong scientific rationale and preliminary data relevant to rare cancers, with a focus on potential high-impact advancements in cancer biology, research models, or novel therapeutic strategies. The total estimated funding for this program is $6.16 million, with a maximum request of $350,000 per project for up to three years, and applications are due by September 23, 2024. Interested applicants can reach out to the CDMRP Help Desk at help@eBRAP.org for further assistance.

Point(s) of Contact
help@eBRAP.org
Files
Title
Posted
HT924524RCRPIDA_GG.pdf
Aug 24, 2024, 2:22 AM UTC
The Department of Defense (DOD) is announcing the FY24 Rare Cancers Research Program (RCRP), specifically offering the Idea Development Award to encourage innovative research on rare cancers, defined as those affecting six or fewer people per 100,000 annually in the U.S. The funding opportunity includes a total of $17.5 million for this fiscal year, with a maximum request of $350,000 per project for up to three years. Applicants must demonstrate the relevance of their research to military personnel, veterans, and the general public, and address at least one of the program's focus areas: cancer biology, research models, or novel therapeutic strategies. The submission process follows a two-step approach: pre-application submission via eBRAP and full application via Grants.gov, with strict adherence to deadlines. Eligible applicants include both extramural and intramural organizations, with independent investigators at or above the Assistant Professor level acting as Principal Investigators. The review process will evaluate the applications based on technical merit, impact on rare cancer outcomes, and the overall effectiveness of the proposed research strategy. The program aims to promote research with the potential for significant advancements in addressing rare cancers and improving patient outcomes.
Similar Opportunities
NCI Small Grants Program for Cancer Research for Years 2023, 2024, and 2025 (NCI Omnibus) (R03 Clinical Trial Optional)
National Institutes of Health
The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced the NCI Small Grants Program for Cancer Research (R03) for the years 2023 to 2025. This funding opportunity is designed to support small-scale research projects on cancer that can be completed within a two-year timeframe and with limited resources, including pilot studies, secondary data analyses, and the development of research methodologies or technologies. Grants of up to $50,000 per year are available to a wide range of eligible applicants, including higher education institutions, nonprofits, and various community organizations. Interested parties should submit their applications electronically via Grants.gov, with the first submission deadline having been January 22, 2023, and subsequent deadlines continuing through 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
DOD USAMRDC FY23-FY27 BROAD AGENCY ANNOUNCEMENT for Extramural Medical Research
Dept. of the Army -- USAMRAA
The Department of the Army, through the U.S. Army Medical Research and Development Command (USAMRDC), has announced the FY23-FY27 Broad Agency Announcement (BAA) for Extramural Medical Research, which is open for submissions from October 1, 2022, to September 30, 2027. This opportunity invites innovative research proposals that address critical military medical challenges, particularly in the areas of Military Infectious Diseases, Combat Casualty Care, and Military Operational Medicine, with a focus on enhancing medical practices for both military personnel and civilians. The BAA emphasizes the importance of collaboration with Department of Defense and Department of Veterans Affairs resources and requires adherence to strict submission guidelines via Grants.gov and the electronic Biomedical Research Application Portal (eBRAP). Interested applicants can submit pre-proposals at any time during the five-year period, with full proposals invited based on initial submissions, and should direct inquiries to the CDMRP Help Desk at help@eBRAP.org.
Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
National Institutes of Health
The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced a funding opportunity titled "Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)." This initiative aims to support exploratory research projects that focus on the early-stage development of innovative technologies for molecular and cellular analysis in cancer research, with an emphasis on enhancing characterization of cancer biology and addressing health disparities. Eligible applicants include a wide range of organizations, such as higher education institutions, non-profits, and tribal governments, with funding available up to $150,000 annually for a project period not exceeding three years. The total estimated funding for this program is approximately $4.2 million, with about 17 awards expected to be made. Interested applicants can find more information and submit inquiries via email to grantsinfo@nih.gov, with applications due by October 3, 2025.
NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)
National Institutes of Health
The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering a funding opportunity titled "NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)" aimed at supporting innovative preclinical and early-phase clinical research in cancer diagnosis, treatment, and prevention. This grant, with a funding ceiling of $275,000 over two years, encourages exploratory studies that may involve significant risk but have the potential to lead to breakthroughs in cancer research, particularly for underserved populations. Applications will be evaluated based on their significance, innovation, and rigor, with key deadlines for submission set for January 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)
National Institutes of Health
The National Institutes of Health (NIH) is offering a funding opportunity through the R21 Clinical Trial Optional mechanism, aimed at supporting exploratory and developmental research in cancer diagnosis, treatment, imaging, symptom management, and prevention. This grant is designed to encourage innovative studies that challenge existing paradigms and address critical barriers in cancer research, particularly focusing on reducing disparities among underserved populations. Eligible applicants include a wide range of organizations, such as historically black colleges, tribal governments, and faith-based organizations, with a maximum funding amount of $275,000 available over a two-year period. Interested parties can find more information and application details at the provided link, with a submission deadline of July 1, 2025, and inquiries directed to the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
Cancer Research Education Grants Program - Research Experiences (R25 Clinical Trial Not Allowed)
National Institutes of Health
The National Institutes of Health (NIH) has announced the "Cancer Research Education Grants Program - Research Experiences (R25 Clinical Trial Not Allowed)," aimed at enhancing the training of a workforce to meet the nation’s biomedical and clinical research needs, particularly in cancer research. This program seeks applications that propose innovative educational activities, specifically hands-on cancer research experiences lasting 8 to 15 weeks, complemented by additional educational initiatives. With a funding ceiling of $300,000 per year for a project period of up to five years, the program encourages participation from underrepresented groups and aims to provide unique educational opportunities not covered by existing programs. Interested applicants can find more information and guidelines at the NIH website, with the application deadline set for January 25, 2026.
Exploratory Grant Award to Promote Workforce Diversity in Basic Cancer Research (R21 Clinical Trial Not Allowed)
National Institutes of Health
The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced the "Exploratory Grant Award to Promote Workforce Diversity in Basic Cancer Research" (R21 Clinical Trial Not Allowed). This funding opportunity aims to enhance diversity among early-stage and junior investigators in cancer research, particularly from groups that are underrepresented in the biomedical, behavioral, clinical, and social sciences. The initiative encourages innovative studies in cancer biology, with a maximum funding amount of $275,000 available over a two-year period, and applications must demonstrate scientific merit and innovation. The application window opens on May 17, 2024, with the first awards expected to be made in June 2024; interested applicants can find more information and submission guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
Exploratory Grants in Cancer Control (R21 Clinical Trial Optional)
National Institutes of Health
The National Institutes of Health (NIH) is offering Exploratory Grants in Cancer Control through the R21 Clinical Trial Optional mechanism, aimed at advancing innovative research in cancer control. This funding opportunity encourages applications focused on behavioral modification, screening, and understanding the etiological factors of cancer, with the goal of developing novel methodologies and tools that can significantly impact population-based cancer research. Grants of up to $275,000 are available for projects lasting up to two years, with application deadlines beginning January 16, 2025, and continuing through 2028. Interested applicants can find more information and submit inquiries via email at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PA-25-253.html.
Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed)
National Institutes of Health
The National Institutes of Health (NIH) has announced a funding opportunity for preclinical proof of concept studies targeting rare diseases under the R21 Exploratory/Developmental Research Grant mechanism. This initiative aims to support efficacy studies in established preclinical models for therapeutic agents, including small molecules and biologics, with the goal of advancing projects toward Investigational New Drug (IND) applications. The funding is particularly significant as it addresses the unmet medical needs of approximately 30 million individuals in the U.S. affected by rare diseases, enhancing the likelihood of progressing novel therapies to clinical trials. The total funding available is up to $1,200,000 for FY26, with a maximum budget of $275,000 per two-year project. Interested applicants must submit their letters of intent by May 1, 2025, and can find more information by contacting NIH Grants Information at grantsinfo@nih.gov or visiting the opportunity's webpage at https://grants.nih.gov/grants/guide/rfa-files/RFA-TR-25-002.html.
Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R21 Clinical Trial Not Allowed)
National Institutes of Health
The National Institutes of Health (NIH) has announced a funding opportunity titled "Microbial-based Cancer Imaging and Therapy - Bugs as Drugs," aimed at exploring innovative strategies for cancer therapy and diagnostics utilizing microorganisms. This R21 grant supports exploratory projects that investigate the interactions between tumors and microorganisms, such as bacteria and viruses, with a focus on enhancing immune responses and developing new imaging technologies, particularly for solid tumors and oral cancers. The initiative seeks to address critical gaps in current cancer treatment modalities and encourages proposals that demonstrate innovative, multi-disciplinary approaches. Eligible applicants can request funding up to $275,000 over a two-year project period, with applications due by May 7, 2025. For further inquiries, interested parties can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov or visit the additional information link at http://grants.nih.gov/grants/guide/pa-files/PAR-22-086.html.